Cinvanti Patent Expiration

Cinvanti is a drug owned by Heron Therapeutics Inc. It is protected by 10 US drug patents filed from 2018 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 18, 2035. Details of Cinvanti's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

Active
US10953018 Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

Active
US9561229 Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

Active
US9974794 Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

Active
US10624850 Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

Active
US9974793 Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

Active
US9974742 Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

Active
US11173118 Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(10 years from now)

Active
US10500208 Emulsion formulations of aprepitant
Sep, 2035

(10 years from now)

Active
US11744800 Methods of use of emulsion formulations of an NK-1 receptor antagonist
Sep, 2035

(10 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cinvanti's patents.

Given below is the list of recent legal activities going on the following patents of Cinvanti.

Activity Date Patent Number
Patent litigations
Patent eCofC Notification 13 Feb, 2024 US11744800
Email Notification 13 Feb, 2024 US11744800
Recordation of Patent eCertificate of Correction 13 Feb, 2024 US11744800
Mail Patent eCofC Notification 13 Feb, 2024 US11744800
Post Issue Communication - Certificate of Correction 22 Jan, 2024 US11744800
Payment of Maintenance Fee, 4th Yr, Small Entity 23 Oct, 2023 US10624850
Email Notification 05 Sep, 2023 US11744800
Patent eGrant Notification 05 Sep, 2023 US11744800
Recordation of Patent Grant Mailed 05 Sep, 2023 US11744800
Patent Issue Date Used in PTA Calculation 05 Sep, 2023 US11744800

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cinvanti is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cinvanti's family patents as well as insights into ongoing legal events on those patents.

Cinvanti's Family Patents

Cinvanti has patent protection in a total of 5 countries. It has a significant patent presence in the US with 71.4% of its patents being US patents. Click below to unlock the full patent family tree for Cinvanti.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Cinvanti's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 18, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cinvanti Generics:

Aprepitant is the generic name for the brand Cinvanti. 3 different companies have already filed for the generic of Cinvanti, with Glenmark Speclt having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cinvanti's generic

How can I launch a generic of Cinvanti before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Cinvanti's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cinvanti's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Cinvanti -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
130 mg/18 mL 29 Apr, 2022 1 18 Sep, 2035

Alternative Brands for Cinvanti

Cinvanti which is used for managing nausea and vomiting in cancer patients undergoing chemotherapy., has several other brand drugs using the same active ingredient (Aprepitant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Heron Theraps Inc
Aponvie
Merck
Emend
Merck And Co Inc
Emend
Msd Merck Co
Emend
Steriscience
Focinvez


Apart from brand drugs containing the same ingredient, some generics have also been filed for Aprepitant, Cinvanti's active ingredient. Check the complete list of approved generic manufacturers for Cinvanti





About Cinvanti

Cinvanti is a drug owned by Heron Therapeutics Inc. It is used for managing nausea and vomiting in cancer patients undergoing chemotherapy. Cinvanti uses Aprepitant as an active ingredient. Cinvanti was launched by Heron Theraps Inc in 2017.

Approval Date:

Cinvanti was approved by FDA for market use on 09 November, 2017.

Active Ingredient:

Cinvanti uses Aprepitant as the active ingredient. Check out other Drugs and Companies using Aprepitant ingredient

Treatment:

Cinvanti is used for managing nausea and vomiting in cancer patients undergoing chemotherapy.

Dosage:

Cinvanti is available in emulsion form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
130MG/18ML (7.2MG/ML) EMULSION Prescription INTRAVENOUS